May 2022 HorizonTherapeutics.com - Horizon Therapeutics
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
May 2022
HorizonTherapeutics.com
Horizon at a Glance
Focused on going to Personally invested in
incredible lengths for our our patients wherever
patient populations they are in their journey
Nearly 2,000 employees Our medicines treat rare, Global headquarters in Dublin,
autoimmune and severe Ireland; U.S. headquarters
inflammatory diseases in Deerfield, Illinois
Proprietary and Confidential Property of Horizon 2
We Are a Science-Based Organization Addressing Unmet
Needs for Underserved Patients
RARE DISEASE AUTOIMMUNE SEVERE INFLAMMATORY
Rare diseases pose a significant and unique Autoimmune diseases are the result of an Severe inflammatory diseases are
challenge in medicine and for the care of individual’s immune system attacking its characterized by inflammation in the body,
these small populations of patients. Only 5 own healthy cells and tissue. These diseases including the joints, muscles and other
percent of the 7,000 known rare diseases often involve autoreactive immune cells bodily systems. This inflammation can cause
have approved treatments1. that may create autoantibodies and result substantial and chronic pain, reduced
in recurring bouts of disease flares followed mobility and difficulty in daily life.
by periods of remission.
1 Miyamoto BE, Kakkis ED. The potential investment impact of improved access to accelerated approval on the development of treatments for low prevalence rare diseases. Orphanet Journal of Rare Diseases. 2011;6(1):49. doi:10.1186/1750-1172-6-49.
Proprietary and Confidential Property of Horizon 3
Updated May 4, 2022
A Pipeline Built With Purpose
Program Potential Indication Preclinical Phase 1 Phase 2 Phase 3
IgG4-Related Disease
UPLIZNA Horizon is exploring the
Myasthenia Gravis
potential of its on-market
Diffuse Cutaneous Systemic Sclerosis medicines to identify paths
HZN-825 for new treatment methods
Idiopathic Pulmonary Fibrosis
and improve patient
Focal Segmental Glomerulosclerosis outcomes.
Kidney Transplant Rejection
Dazodalibep
(HZN-4920)
Rheumatoid Arthritis • Quantifying the impact
of TEPEZZA for patients
Sjögren’s Syndrome
with chronic Thyroid
Alopecia Areata Eye Disease
Dermatomyositis
• Evaluating efficacy and
Daxdilimab
Discoid Lupus Erythematosus safety of KRYSTEXXA in
(HZN-7734)
broader patient
Lupus Nephritis populations with
Systemic Lupus Erythematosus
retreatment (ADVANCE)
TED in Japan (OPTIC-J) • Exploring the patient
experience with
TEPEZZA Diffuse Cutaneous Systemic Sclerosis
KRYSTEXXA – monthly
Subcutaneous Administration dosing (FORWARD) and
shorter infusion
HZN-1116 Autoimmune Diseases
durations (AGILE)
Alpine Autoimmune Diseases
Arrowhead Next-Gen Uncontrolled Gout
HemoShear Novel Gout Targets
Proprietary and Confidential Property of Horizon 4
Our Commitment Beyond Our Medicines
We Participate, Listen and Learn with Our Disease
Communities
+60 +1,000
Patient advocacy group Employees take part in hundreds
partnerships globally of advocacy events around the world
Proprietary and Confidential Property of Horizon 6
We Create Change in Our Community: Annual Impact
+60 $1B $3.7M
Non-profits Provided in COVID-19 relief
supported patient support
4 $20M+ $500K+ 11
Pillars of giving in In support Racial equity Of the 17 United
healthcare, STEAM, of our communities response Nations Sustainable
environmental Development Goals
sustainability and supported
innovation
Proprietary and Confidential Property of Horizon 7
“Going above and beyond for
patients is what we do every day.
It is at the core of our company
culture and reflects my own
experience as a patient.”
Tim Walbert
Chairman, President and CEO
Working At Horizon Isn’t Just A Job. It’s Personal.
Thank you
HorizonTherapeutics.com
You can also read
